William “Brad” Schenkel, MS’01
Recently, TDI had a chance to connect with Brad Schenkel, MS’01, about his experience at the Center for the Evaluative Clinical Sciences (now The Dartmouth Institute), how it impacts his work, and what he is doing now.
What brought you to Dartmouth and the CECS program?
I was living in New York City at the time and working as a Clinical Research Associate at Memorial Sloan-Kettering Cancer Center. My education and work experience up to that point had been almost entirely devoted to the sciences, including completing the pre-medical curriculum at Middlebury College. I decided that I really wanted to add business and economics to my skill sets and hopefully embark on a career that was able to blend both science and economics. Thankfully, I was made aware of the Center for the Evaluative Clinical Sciences (now TDI) through a friend who was then enrolled in the program. After I did some research on the program, and certainly given the great reputation of Dartmouth, I jumped at the chance to apply.
How do you use TDI in your everyday work?
It was my double major in economic evaluation and health policy that truly launched my interest in clinical research and health care. Without that initial interest, I would not have ended up at CECS. I truly enjoyed all of my coursework at CECS, including epidemiology, biostatistics, and decision analysis. My studies at CECS could not be more applicable to the work that I now do at Johnson & Johnson (J&J) Scientific Affairs, all of which I employ at J&J. Nearly 14 years later, I remain a health economist at J&J. I’m extremely satisfied in my role, and I know that I really owe my career to the Dartmouth CECS program.
Any words of wisdom for incoming TDI students?
I think TDI students have a world of opportunities available to them. The coursework offered through the program is really at the cutting edge of health care, perfectly readying students to play a meaningful role in the quickly evolving health care environment, including all the changes ongoing in health care reform. It’s wonderfully applicable to so many different types of students, including physicians, nurses, college graduates, and many more. I honestly feel there’s no limit to the kinds of rewarding health care careers that one can attain after graduating from the program and I think TDI is the perfect launching pad for an exciting and rewarding career in health care.
Brad is a Director in the Janssen Scientific Affairs, Health Economics and Outcomes Research (HECOR) Team. Within this team, Brad leads HECOR research projects and strategy for Ibrutinib within the oncology therapeutic area. Prior to joining the HECOR team, Brad was a member of the Worldwide Market Access team responsible for health economics and outcomes research in oncology, dermatology, and immunology, including health economics research projects, meta-analyses, patient reported outcomes studies, and prospective observational and retrospective studies across global markets. Brad has 13 years of experience working in the pharmaceutical sector of Johnson & Johnson.